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Activation of the NLRP3 inflammasome induces maturation of IL-
1β and IL-18, both validated targets for treating acute and chronic
inflammatory diseases. Here, we demonstrate that OLT1177,
an orally active β-sulfonyl nitrile molecule, inhibits activation of the
NLRP3 inflammasome. In vitro, nanomolar concentrations of OLT1177
reduced IL-1β and IL-18 release following canonical and noncanonical
NLRP3 inflammasome activation. The molecule showed no effect on
the NLRC4 and AIM2 inflammasomes, suggesting specificity for
NLRP3. In LPS-stimulated human blood-derived macrophages,
OLT1177 decreased IL-1β levels by 60% and IL-18 by 70% at concen-
trations 100-fold lower in vitro than plasma concentrations safely
reached in humans. OLT1177 also reduced IL-1β release and caspase-
1 activity in freshly obtained human blood neutrophils. In mono-
cytes isolated from patients with cryopyrin-associated periodic
syndrome (CAPS), OLT1177 inhibited LPS-induced IL-1β release by
84% and 36%. Immunoprecipitation and FRET analysis demonstrated
that OLT1177 prevented NLRP3-ASC, as well as NLRP3-caspase-1 in-
teraction, thus inhibiting NLRP3 inflammasome oligomerization. In a
cell-free assay, OLT1177 reduced ATPase activity of recombinant
NLRP3, suggesting direct targeting of NLRP3. Mechanistically,
OLT1177 did not affect potassium efflux, gene expression, or syn-
thesis of the IL-1β precursor. Steady-state levels of phosphorylated
NF-κB and IkB kinase were significantly lowered in spleen cells
from OLT1177-treated mice. We observed reduced IL-1β content
in tissue homogenates, limited oxidative stress, and increasedmuscle
oxidative metabolism in OLT1177-treated mice challenged with LPS.
Healthy humans receiving 1,000mg of OLT1177 daily for 8 d exhibited
neither adverse effects nor biochemical or hematological changes.
interleukin-1 | NLRP3 | caspase-1
Interleukin-1β (IL–1β) is the prototypic inflammatory cytokinethat promotes acute and chronic inflammation in a broad
spectrum of diseases (1). Lacking a leader sequence, the IL-1β
precursor requires maturation into an active cytokine by caspase-
1. Activation of caspase-1 takes place by the oligomerization of
intracellular proteins, termed inflammasomes, which induce the
autocatalytic activation of caspase-1 (2, 3). Whereas several
inflammasomes have been described, the NOD-like receptor
(NLR) protein 3 (NLRP3) (also known as cryopyrin) has been
extensively characterized for its role in models of disease (4, 5).
Processing and secretion of active IL-1β and IL-18 via caspase-1
follows activation of the NLRP3 inflammasome. Pharmacologic
inhibition or genetic deficiency of NLRP3 results in markedly
reduced inflammation in animal models of human disease (6–8).
Microbial products via Toll-like receptors (TLRs), host products
generated during damaging inflammation, as well as IL-1 itself,
activate NLRP3, which leads to release of active IL-1β and IL-18.
Although neutralization of IL-1β has proven efficacious in the
treatment of inflammation, to date, there is no approved therapeutic
that inhibits the activation of the NLRP3 inflammasome in humans.
OLT1177 is an active moiety discovered during the investigation
of synthetic reactions containing chlorinating agents and methio-
nine. Structural elucidation established that OLT1177 is a β-sulfonyl
nitrile (formula weight 133.17). We report here that OLT1177 is
a selective inhibitor of the NLRP3 inflammasome. We also re-
port that, in healthy humans, OLT1177 is safe at oral doses up to
1,000 mg each day for 8 d, with no clinical, hematological, or
organ toxicities observed. Thus, OLT1177 has the potential for
the treatment of IL-1β– and IL-18–mediated diseases.
Significance
The NLRP3 inflammasome is an intracellular oligomer regulat-
ing the activation of caspase-1 for the processing and secretion
of IL-1β and IL-18. Although there is growing evidence to
substantiate inflammasome inhibition as a therapeutic option
for the treatment of inflammatory diseases, to date, there are
no approved humans agents. OLT1177, a β-sulfonyl nitrile
molecule, shown to be safe in humans, is a selective inhibitor
of the NLRP3 inflammasome, with unique properties to reverse
the metabolic costs of inflammation and to treat IL-1β– and IL-
18–mediated diseases.
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Results
OLT1177 Suppresses IL-1β and IL-18 Release with No Effect on Priming
or TNFα. The structure of OLT1177 is depicted in Fig. 1A and is
verified as described in SI Appendix, Figs. S1–S4. We evaluated
the effect of OLT1177 on cytokine production in murine and
human macrophages following NLRP3 inflammasome activa-
tion. In the murine macrophages cell line J774A.1, nanomolar
concentrations of OLT1177 reduced IL-1β secretion by 50%
following LPS/ATP stimulation (Fig. 1B). In human monocyte-
derived macrophages (HMDMs), OLT1177 showed maximal
inhibition (60%) of IL-1β and (70%) of IL-18 secretion at 1 μM
(SI Appendix, Fig. S5 A and B). By Western blotting, mature IL-
1β and the generation of the p10 subunit of active caspase-1
were reduced in the supernatant at 1 and 10 μM OLT1177 (Fig.
1C). In cell lysates, activated caspase-1 was reduced by 35%
(P = 0.003) (SI Appendix, Fig. S5C) whereas there were no
changes in the intracellular level of the IL-1β and caspase-1 pre-
cursors (Fig. 1 C and D). In the same supernatants, OLT1177
showed no effect in TNFα levels (Fig. 1E). Similar to cultures
stimulated with LPS/ATP, OLT1177 inhibited IL-1β release in
murine macrophages stimulated with LPS and nigericin (Fig. 1F),
without affecting TNFα levels (Fig. 1G). Although LPS/ATP
stimulation can result in lactate dehydrogenase (LDH) release as
a measure of cell death, in the presence of OLT1177, the release
of LDH was significantly reduced (P < 0.05) (Fig. 1H). To further
investigate potential effects of OLT1177 on gene expression,
mRNA levels of nlrp3, asc, caspase1, il1b, and il18 were measured.
As shown in SI Appendix, Fig. S5 D–H, OLT1177 had no effect on
mRNA levels of these genes, suggesting no effect on the priming
phase of the NLRP3 inflammasome formation.
A B C
D E F
G H
Fig. 1. OLT1177 reduces IL-1β but not TNFα following NLRP3 inflammasome activation. (A) OLT1177 structure. (B) Mean ± SEM percent change (range 270 to
860 pg/mL) of secreted mature IL-1β from J774A.1 cells stimulated with LPS and ATP in the presence of increasing concentration of OLT1177. (C) Western blots
for IL-1β (p17 and IL-1β precursor) and caspase-1 (p10 and p45) of supernatant (Sup) and cell lysates (Lys) from J774A.1 cells stimulated with LPS and ATP in the
presence of OLT1177. (D) Mean ± SEM percent change (range 375 to 720 pg/mL) of total IL-1β protein level from J774A.1 cell lysates stimulated with LPS and
ATP in the presence of OLT1177. (E) Mean ± SEM percent change (range 4,060 to 18,800 pg/mL) of secreted mature TNFα from J774A.1 cells stimulated with
LPS and ATP in the presence of increasing concentration of OLT1177. (F and G) Mean ± SEM percent change of secreted mature IL-1β (range 100 to 3,024 pg/mL)
(F) and TNFα (range 10,900 to 14,300 pg/mL) (G) from J774A.1 cells stimulated with LPS and nigericin (NIG) in the presence of OLT1177. (H) Mean ± SEM of LDH
from J774A.1 cells stimulated with LPS and ATP in the presence of increasing concentration of OLT1177. Percent changes are calculated as described inMethods.
The black bars represent the percent of IL-1β, TNFα, and LDH that is still expressed after treatment. ***P < 0.001, *P < 0.05. Data are representative of three
independent experiments.
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Noncanonical activation of the NLRP3 inflammasome by in-
tracellular LPS leads to an alternative inflammasome pathway, medi-
ated by caspase-4 in humans and caspase-11 in mice (9). We examined
IL-1β release in human THP-1 cells stimulated with the TLR2/4 ago-
nist Pam3CSK4, followed by transfection with LPS in WT and nlrp3-
deficient cells. As shown in SI Appendix, Fig. S6, treatment with
OLT1177 reduced IL-1β release in THP-1 cells, with maximal in-
hibition (70%) at 10 μM (P < 0.001). Cells deficient in nlrp3 showed
low or no production of IL-1β, confirming the requirement of
NLRP3 for IL-1β release in this model (SI Appendix, Fig. S6).
Ct
rl
Ve
hic
le
OL
T
0
200
400
600
800
1000
1200
FR
ET
  N
LR
P3
-A
SC
(a
.l.
u.
f.i
 )
LPS/NIG
***
I
Ve
hic
le
NL
RP
3
OL
T 1
0
M
OL
T 1
M
BA
Y 1
0
M
MN
S 1
0
M
0
5000
10000
15000
AT
Pa
se
 a
ct
iv
ity
 
(U
ni
t o
f l
um
in
es
ce
nc
e) **
**
Ct
rl
Ve
hic
le
OL
T
0
50
100
150
FR
ET
  N
LR
P3
-C
as
pa
se
-1
(%
 L
PS
/N
IG
)
LPS/NIG
***
J
B
IP: NLRP3
A
LP
S/N
IG
OL
T 1
0
M
OL
T 1
M
0.0
0.5
1.0
1.5
O
D
(A
SC
/N
LR
P3
)
*
*
ASC
Ct
rl
Ve
hi
cl
e
O
LT
 (1
0
M
)
O
LT
 (1
M
)
LPS/NIG
D E
F G H
Ctrl LPS/NIG LPS/NIG/OLT
NLRP3 ASC DAPI NLRP3 ASC DAPI NLRP3 ASC DAPI
C
10 M
Fig. 2. OLT1177 inhibits NLRP3 inflammasome formation. (A) Immunoprecipitation (IP, Left) and analysis (Right, mean of 3 ± SEM) of the NLRP3-ASC association in
J774A.1 cells stimulated with LPS/nigericin (NIG). (B) ATPase activity of recombinant NLRP3 in the presence of OLT1177 (n = 3), Bay11-7082 (BAY) (n = 2), and 3,4-
methylenedioxy-β-nitrostyrene (MNS) (n = 2). (C–E) Immunofluorescent staining and (F–H) FRET fromNLRP3 (in red) and ASC (in green) in J774A.1 cells stimulated with
LPS and NIG in presence of OLT1177 (10 μM). Representative ASC speck-like structures are indicated (white arrows) and highlighted in the Inset (D). Images were
acquired using Slide Book 6 (Intelligent Imaging Innovation). (I and J) Mean ± SEM of FRET intensity from NLRP3-ASC (I) and percent change of FRET intensity from
NLRP3-caspase-1 (J). ***P < 0.001, **P < 0.01, *P < 0.05. The data are mean of three independent experiments. a.l.u.f.i., arbitrary linear units of fluorescence intensity.
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We next examined the effect of OLT1177 on downstream
kinase phosphorylation activity in HMDM stimulated with LPS
and nigericin. As depicted in SI Appendix, Fig. S7A, OLT1177
reduced several phosphorylated kinases. For example, there was
a 26% reduction in Src activation, which, among other functions,
activates the NF-κB pathway (10, 11); a 35% reduction in Fyn,
which is involved in T-cell activation and motility (12, 13); a 43%
reduction in the neutrophil activating kinase Hck (14); and a
33% reduction in STAT3, which affects autoimmune diseases
and cancer (15). To demonstrate that OLT1177 does not influ-
ence LPS-mediated NF-κB activation, we used the specific IκB
kinase inhibitor (IKKi) (ACHP). As shown in SI Appendix, Fig.
S7B, ACHP reduced LPS/nigericin induction of IL-1β by 60%;
however, in combination with OLT1177, the release of IL-1β was
to the levels of unstimulated cells.
OLT1177 Prevents NLRP3 Inflammasome Formation. In J774A.1 cells,
ASC immunoprecipitated with NLRP3 following LPS and niger-
icin, confirming the formation of the oligomer upon stimulation of
the inflammasome (Fig. 2A). OLT1177 treatment resulted in a
reduction in the NLRP3-mediated ASC recruitment (Fig. 2A, Left
and Right). Using full-length recombinant human NLRP3 protein,
we next measured the effect of OLT1177 on the nucleotide-
binding domain of NLRP3. Recombinant NLRP3 exhibited
ATPase activity (Fig. 2B), which was inhibited by OLT1177 at
1 and 10 μM (Fig. 2B). In the same assay, known inhibitors of the
NLRP3 inflammasome, BAY and MNS, were used as positive
controls (16, 17).
We next investigated the effect of OLT1177 on NLRP3
inflammasome formation using immunofluorescence and fluo-
rescent resonance energy transfer (FRET) analysis. In unsti-
mulated J774A.1 cells, NLRP3, ASC, and caspase-1 were diffuse
in the cell (Fig. 2C and SI Appendix, Fig. S9A). However, fol-
lowing LPS and nigericin, ASC oligomerization was observed in
the characteristic speck-like structure in the cytosol of J774A.1
cells (Fig. 2D). Cells treated with OLT1177 showed a reduction
in speck structures, suggesting reduced inflammasome formation
(Fig. 2E). ASC-NLRP3 association was further confirmed using
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Fig. 3. OLT1177 has no effect on ATP-induced ion currents and on NLRC4 and AIM2 inflammasomes. (A) Representative current change of whole-cell patch-
clamp measurements performed on human U937 cells primed with LPS (1 μg/mL, 5 h) and treated with BzATP (100 μM) to induce P2X7R activation.
(B) Treatment with 100 μMOLT1177 in parallel cultures following BzATP. (C) Analysis of multiple measurements of BzATP-induced current changes (ΔIBzATP) in
the absence and presence of OLT1177 (0.1 nM and 100 μM, Wilcoxon signed-rank test). ΔIBzATP values are shown as individual data points, bars represent
median, and whiskers percentiles 25 and 75. (D and E) Mean ± SEM of secreted mature IL-1β and TNFα from J774A.1 cells stimulated with LPS and flagellin
(Flag) in the presence of OLT1177. (F and G) Mean ± SEM of secreted mature IL-1β and TNFα from J774A.1 cells stimulated with LPS and Poly (dA:dT) in the
presence of OLT1177 as measured in the supernatants. Data are derived from three independent experiments.
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FRET. FRET positivity requires the distance between two
molecules, in this case NLRP3 and ASC, to be less than 30 nm.
As shown in Fig. 2G, LPS and nigericin stimulation of
J774A.1 cells showed higher FRET intensity for NLRP3 and
ASC, indicating inflammasome oligomerization. Following treat-
ment with OLT1177, the association between these two proteins
was significant lower (Fig. 2 H and I). FRET analysis was also
conducted to measure the proximity of NLRP3 and caspase-1 (SI
Appendix, Fig. S9A). OLT1177 reduced NLRP3 and caspase-1 as-
sociation following LPS and nigericin (Fig. 2J and SI Appendix, Fig.
S9). Taken together, these data demonstrate that OLT1177 reduces
the release of mature IL-1β by preventing NLRP3 inflammasome
oligomerization.
OLT1177 Has No Effect on ATP-Induced Ion Current and Has No Effect
on AIM2 and NLRC4 Inflammasomes. We next investigated the ef-
fect of OLT1177 on K+ efflux, a common activator of inflam-
masome function via activation of the P2X7 receptor (P2X7R)
by extracellular ATP (18, 19). Ion current was measured in hu-
man LPS-primed monocytic U937 cells by whole-cell patch-clamp
measurements. Two successive applications of 100 μM 2′(3′)-O-(4-
benzoylbenzoyl)adenosine-5′-triphosphate tri(triethylammonium)
salt (BzATP) resulted in the expected current change due to
P2X7R activation (Fig. 3A); however, this was not affected by
OLT1177 (Fig. 3 B and C). The lack of effect of OLT1177 on ion
flux was confirmed using Xenopus laevis oocytes, which heterolo-
gously express human P2X7R. OLT1177 had no effect on ion flux
in oocytes when treated with BzATP (SI Appendix, Fig. S10). We
conclude that OLT1177 inhibits NLRP3 inflammasome activa-
tion by a mechanism downstream of P2X7R.
To investigate the potential effect of OLT1177 on other
inflammasomes, murine macrophages were primed with LPS and
stimulated with either flagellin to activate the NLRC4 inflam-
masome or the dsDNA analog Poly(dA:dT) to activate the
AIM2 inflammasome. The release of IL-1β and TNFα was de-
termined. Compared with the levels induced by the agonists,
OLT1177 showed no effect on the release of these cytokines
following NLRC4 (Fig. 3 D and E) or AIM2 (Fig. 3 F and G)
inflammasome activation. These data indicate that OLT1177 is
specific for the NLRP3 inflammasome.
OLT1177 Reduces IL-1β Release in Freshly Obtained Human Blood
Neutrophils. Neutrophil recruitment and tissue infiltration are
hallmarks of the inflammatory response to injury and infection.
Therefore, we investigated the effect of OLT1177 on freshly
obtained human blood neutrophils following LPS and ATP stim-
ulation. Processing and release of IL-1β precursor in primary
human neutrophils was observed in cells stimulated with LPS and
ATP (Fig. 4A). OLT1177 prevented the release of IL-1β (Fig. 4A)
without affecting the total intracellular pool of the IL-1β precursor
(Fig. 4B). Treatment of neutrophils with OLT1177 also reduced
caspase-1 activity at 50 and 10 μM (Fig. 4C) without affecting il1b,
caspase1, and nlrp3 mRNA levels (Fig. 4 D–F).
OLT1177 Reduces the Severity of LPS-Induced Systemic Inflammation
in Vivo. We next examined the efficacy of OLT1177 treatment
in mice challenged with LPS-induced systemic inflammation.
A B C
D E F
Fig. 4. OLT1177 reduces IL-1β release, caspase-1 activity in primary human blood neutrophils. (A) IL-1β levels in the supernatants from primary human
neutrophils stimulated with LPS and ATP in the presence of concentrations of OLT1177 (0.1, 1, and 10 μM) by ELISA (Below) and Western blot (Above) (mature
17 kDa IL-1β). (B) IL-1β precursor levels in the lysates of the cells shown in A. (C) Caspase-1 activity in human neutrophils following LPS/ATP in the presence of
OLT1177. Data are expressed as mean ± SEM of neutrophils from three healthy donors. (D–F) Fold change of mRNA levels from neutrophils stimulated with
LPS and ATP in the presence of OLT1177. Data are expressed as mean ± SEM of cells from four healthy donors. ***P < 0.001, **P < 0.01, *P < 0.05.
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As shown in Fig. 5 A–C, OLT1177 significantly reduced peritoneal
fluid myeloperoxidase (MPO) by 80%, the neutrophil chemokine
(C-X-C motif) ligand 1 (CXCL1) by 30%, and IL-6 by 44%. The
total IL-1β content in lung, liver, spleen, and skeletal muscle was
also significantly decreased (Fig. 5D); no significant changes were
detected for TNFα content in these tissues (Fig. 5E).
OLT1177 Increases Oxidative Metabolism in Vivo.Marked alterations
in muscle metabolism are observed during acute and chronic
inflammation (20, 21). We investigated the effect of OLT1177 on
metabolic changes in muscle following LPS-induced systemic
inflammation. Muscle tissue was excised 2 h after LPS admin-
istration and examined for metabolic changes (Fig. 6). Treat-
ment of mice with OLT1177 decreased metabolites of oxidative
stress with increased reduced glutathione (GSH) and decreased
oxidized glutathione (GSSG) levels, leading to an increased
GSH/GSSG ratio (Fig. 6 A–C). Improved glutathione homeo-
stasis in OLT1177-treated mice could be explained, in part, by an
increase in the NADPH-generating pentose phosphate pathway,
for antioxidant effects or to sustain nucleoside anabolism,
which is reflected by increased ribose phosphate levels (Fig.
6D). Since pentose phosphate moieties can also fuel the nu-
cleoside biosynthetic pathways, we determined the relative levels
of high energy purine nucleosides (ATP) and the total levels of
adenylate metabolites (ATP, ADP, and AMP). As shown in Fig. 6
E and F, higher levels of ATP were measured in muscle tissue from
mice treated with OLT1177. These higher levels of adenylate me-
tabolites can be due to increased adenylate synthesis or decreased
consumption of high energy phosphate compounds, both hallmarks
of cell activation following LPS stimulation (22). Consistent with a
reduction in oxidative stress, steady-state levels of TCA cycle in-
termediate α-ketoglutarate were increased in OLT1177-treated
animals (Fig. 6G). Treatment with OLT1177 also showed accu-
mulation of citrate and decreased levels of oxaloacetate (Fig. 6 H
and I). These data are indicative of activation of early oxidative
reactions of mitochondrial metabolism. Consistent with increased
oxidative metabolism, tissue levels of the proinflammatory meta-
bolic marker succinate were decreased in response to OLT1177
administration (Fig. 6J).
Effects of Treatment with OLT1177 on Constitutive Kinase Phosphorylation
in Vivo. Mice were treated with OLT1177, and spleen cells were
isolated and studied ex vivo for changes in phosphorylation of
NF-κB, IκB, IKK, and interleukin-1 receptor-associated kinase 4
(IRAK4). As shown in Fig. 7A, compared with vehicle-treated
mice, steady-state constitutive phosphorylated NFκB was signifi-
cantly reduced in mice treated with OLT1177 at the time of spleen
cell isolation. There were no statistically significant changes in the
other kinases (Fig. 7 B–D). However, when spleen cells from
OLT1177-treated mice were activated in vitro with LPS, there was
a significant reduction in phosphorylated NF-κB, IκB, and IKK
after 30 min, with no change in IRAK4 (Fig. 7 E–H). Thus,
OLT1177 primes these kinases in vivo to be less responsive to an
inflammatory stimulus.
OLT1177 Reduces IL-1β Release in Cells from Subjects with NLRP3
Mutations. OLT1177 was tested in adherent monocytes from
patients affected by cryopyrin-associated periodic syndrome
(CAPS), a rare autoinflammatory disease characterized by gain-
of-function mutations in NLRP3 (23). Patients with CAPS suffer
from recurrent episodes of systemic inflammation, fever, and
debilitation (24, 25). Blood monocytes isolated from two CAPS
patients were stimulated with LPS in the presence and absence
of OLT1177, which was added 30 min following LPS. As shown
in Fig. 8, OLT1177 reduced IL-1β levels in the supernatants by
84% and 36%, respectively.
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Fig. 5. OLT1177 reduces LPS-induced inflammation in vivo. (A–C) Mean ± SEM percent change of (A) myeloperoxidase (MPO) (range 1,755 to 1,870 pg/mL),
(B) CXCL1 (range 971 to 10,200 pg/mL), and (C) IL-6 (range 807 to 1,580 pg/mL) in vehicle (round symbol) and OLT1177-treated group (square symbol) in the
peritoneal fluid 2 h after i.p. LPS (5 mg/kg). Data are expressed as percent change in vehicle-treated mice. (D and E) Mean ± SEM percent change of IL-1β
(range 70 to 1,242 pg/mL) (D) and TNFα (range 70 to 301 pg/mL) (E) level in organ homogenates of mice treated with OLT1177 (square symbol) relative to
vehicle (round symbol). Percent changes are calculated as described in Methods. n = 7 to 8 mice per group. ***P < 0.001, **P < 0.01, *P < 0.05.
Marchetti et al. PNAS | Published online January 29, 2018 | E1535
IM
M
U
N
O
LO
G
Y
A
N
D
IN
FL
A
M
M
A
TI
O
N
PN
A
S
PL
U
S
Human Pharmacokinetic Profile. Following a single oral dose,
the group mean plasma maximum concentrations (Cmax) were
2,700 ng/mL for the 100-mg dose, 9,800 ng/mL for the 300-mg dose,
and 32,000 ng/mL for the 1,000-mg dose (Fig. 9). The mean plasma
elimination half-life for each group was 23.0, 22.8, and 24.2 h for the
100-mg, 300-mg, and 1,000-mg dose groups, respectively. Mean
pharmacokinetic parameters for OLT1177 after a single dose in
fasted subjects are summarized in SI Appendix, Table S1. Plasma
OLT1177 exposure was also measured after repeated daily oral
dosing. Mean plasma concentrations of OLT1177 (±SD) on the
first (day 1) and last (day 8) of 8 d of oral dosing are presented in SI
Appendix, Fig. S11. The mean group maximum concentrations on
day 8 were 4,800 ng/mL for the 100-mg dose, 15,800 ng/mL for the
300-mg dose, and 41,400 ng/mL for the 1,000-mg dose. The plasma
elimination half-life for each multidose group on day 8 and other
pharmacokinetic parameters for OLT1177 after multiple doses
in fasted subjects are summarized in SI Appendix, Table S2.
OLT1177 Safety Profile. Seven of 35 subjects reported a total of
seven treatment-emergent adverse events (SI Appendix, Table S3),
and one subject reported a non–treatment-emergent adverse
event (AE) during the course of the study. Five of the seven
events occurred after a single dose of OLT1177, and two oc-
curred during the multidose regimen (both in the 100-mg dose
group). The reported AEs were considered to be unrelated to
OLT1177 by the investigator, and each resolved spontaneously.
Physical examination in the subjects exposed to OLT1177
revealed no change from the predrug examination. Systolic and
diastolic blood pressure, heart rate, and body temperature
showed minor fluctuations from baseline to the end of the
study. Overall, there was no correlation between changes in
vital signs and OLT1177 dose or timing of treatment. No sig-
nificant changes were observed in hematologic or coagulation
values at any time during the study, compared with baseline
values. In addition, there were no significant changes from
baseline in serum lipids, urinalysis, liver function enzymes, or
acute phase proteins in any cohort after eight consecutive days
of up to 1,000-mg dosing.
Discussion
Although inhibition of the NLRP3 inflammasome reduces in-
flammation in murine models of acute and chronic inflammatory
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diseases (6, 17, 26), there is currently no approved inflamma-
some inhibitor for human use. Here, we characterize the sulfonyl
nitrile compound OLT1177 as a specific inhibitor of the
NLRP3 inflammasome, with no effect on the NLRC4 and
AIM2 inflammasomes. Unlike other NLRP3 inhibitors (27), we
report here the findings of OLT1177 administered orally to
healthy subjects in a phase 1 study. As presented, OLT1177 was
safe and well-tolerated and achieved meaningful exposure and a
long half-life without any clinical, hematological, or organ tox-
icities observed at any dose tested.
In addition, adherent monocytes from two patients with CAPS
were stimulated with LPS and released less IL-1β in vitro in the
presence of 1 μM OLT1177.
We investigated the properties OLT1177 in human blood
monocyte-derived macrophages, human and murine cell lines,
and primary human blood neutrophils. Neutrophils play a
pathological role in many acute diseases, and elevated blood
neutrophil counts are characteristic of autoinflammatory dis-
eases mediated by IL-1β: for example, acute gout flares (28–30)
and familial Mediterranean fever (31–33). We observed that
OLT1177 reduces the processing of the IL-1β precursor in freshly
obtained human neutrophils, with no change in caspase1, nlrp3, and
il1b mRNA.
OLT1177 treatment consistently reduced IL-1β release from
human blood macrophages, differentiated THP-1 cells, and the
murine macrophage cell line J774A.1. We observed that the in vitro
concentration of OLT1177 necessary to reduce IL-1β differed
among cell types and experimental conditions. We also compared
OLT1177 with MCC950, a reported NLRP3 inflammasome
inhibitor (6) in J774A.1 cells. OLT1177 reduced IL-1β secretion
in a comparable manner compared with MCC950 following
activation of the NLRP3 inflammasome with LPS and ATP (SI
Appendix, Fig. S8). Nevertheless, OLT1177 significantly reduced IL-
1β release at 1 μM or lower concentrations in vitro. By comparison,
mean peak plasma levels after a single oral dose in humans reached
concentrations of 20.3, 73.6, and 240.3 μM, respectively, for doses of
100, 300, and 1,000 mg per subject. Subjects also received 100, 300, or
1,000 mg/d for eight consecutive days, which resulted in mean
maximum plasma concentrations at steady state of 36.0, 118.6, and
310.9 μM, respectively. Thus, based on the observed in vitro potency
levels, OLT1177 reaches effective plasma levels in vivo at molar
concentrations greater than 100-fold those needed to inhibit
activation of the NLRP3 inflammasome in vitro.
NLRP3 inflammasome formation also induces maturation and
release of IL-18. Consistent with inhibition of the NLRP3
inflammasome activation, OLT1177 significantly reduced IL-
18 release in human monocyte-derived macrophages (70% in-
hibition at 1 μM). Preclinical studies reveal that IL-18 is a target
in several models of inflammation (34), including heart failure
(35) and macrophage activation syndrome (MAS) (36), each
treated with IL-1β blockade by the IL-1β antagonist anakinra.
These and other data (35) support the concept that IL-1 drives
the activation of caspase-1, resulting in increased IL-18 process-
ing and release. In patients with CAPS, a classic NLRP3 gain-of-
function disease, blocking IL-1 with anakinra reduced caspase-1
blood monocyte caspase-1 mRNA levels (37).
FRET analysis confirmed that LPS/nigericin treatment results
in the formation of NLRP3-ASC and NLRP3-(pro)caspase-1 com-
plexes at a distance of less than 30 nm, which was significantly re-
duced in the presence of OLT1177. Inhibition of the NLRP3-ASC
oligomerization by OLT1177 was confirmed by immunoprecipita-
tion. The central domain of NLRP3 exhibits nucleotide-binding
properties associated with ATPase activity, which is required for the
NLRP3 self-oligomerization and ASC recruitment (38). In a cell-
free system, OLT1177 inhibited ATPase activity, suggesting a direct
interaction with the NLRP3 protein.
The P2X7 receptor plays a crucial role in inflammasome ac-
tivation and ion currents (19). Here, we show that OLT1177
reduces NLRP3 inflammasome activation and IL-1β release sub-
sequent to ATP and nigericin stimulation, which induce K+ efflux.
However, OLT1177 does not affect K+ efflux, and we conclude
that the properties of OLT1177 are independent of ion currents.
We assessed the in vivo effect of OLT1177 following systemic
administration of LPS in mice. Treatment with OLT1177 limited
LPS-induced acute inflammatory response by reducing MPO,
CXCL1, and IL-6 levels in the peritoneal fluid and IL-1β in
whole tissue homogenates. Secondary effects of OLT1177 when
administered in vivo are likely to be downstream from NLRP3
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Fig. 7. OLT1177 reduces phosphorylation of NF-κB. (A–D) Mean ± SEM of NF-κB, IκB, IKK, and IRAK4 phosphorylation measured in fresh CD11b+CD3− spleen-
derived cells from mice treated with saline (vehicle) or OLT1177 under steady-state conditions. (E–H) Mean ± SEM of NF-κB, IκB, IKK, and
IRAK4 phosphorylation measured in CD11b+CD3− spleen-derived cells from mice treated with saline (vehicle) or OLT1177 stimulated for 30 min with LPS. n = 3
mice per group. **P < 0.01, *P < 0.05.
Marchetti et al. PNAS | Published online January 29, 2018 | E1537
IM
M
U
N
O
LO
G
Y
A
N
D
IN
FL
A
M
M
A
TI
O
N
PN
A
S
PL
U
S
inflammasome activation. For example, without LPS stimulation,
constitutive levels of phosphorylated NF-κB were decreased in
spleen cells from mice treated with OLT1177. Systemic in-
flammation affects cell metabolism as it represents the energy
costs of inflammation. Metabolic derangements, such as the
Warburg effect, have been well-characterized in tumors (39)
when malignant cells produce energy via glycolysis (39).
Proinflammatory stimuli, i.e., LPS, activate macrophages and
dendritic cells, driving systemic and tissue metabolic reprog-
ramming similar to that of the Warburg effect (22, 40, 41). We
show here that OLT1177 protects from LPS-induced oxidative
stress, by promoting glutathione homeostasis. The steady-state
observations suggest increased fluxes through the pentose
phosphate pathway in muscle of OLT1177-treated mice, which
may explain the improved redox state observed. Additionally,
accumulation of pentose phosphate moieties may fuel the
biosynthesis of high energy phosphate nucleosides, contributing
to the improved energy balance observed in the muscles of
OLT1177-treated mice.
OLT1177 treatment also resulted in the accumulation of cit-
rate, with a reduction in oxaloacetate, which limits LPS-induced
citrate metabolism (42, 43). Indeed, succinate levels correlate
with the stabilization of HIF-1α and the induction of proin-
flammatory cascades leading to the accumulation and release
of IL-1β (44). In the present study, we showed that, parallel to
decreased IL-1β levels, OLT1177 also reduced muscle succi-
nate levels. Succinate accumulation is mostly driven by mito-
chondrial uncoupling at the electron transport chain level,
secondary to increased oxidative stress. Here, we show that
OLT1177 promotes mitochondrial metabolism in a tissue with
high energy demands while preventing the accumulation of
proinflammatory succinate.
Methods
OLT1177 Synthesis. The drug substance was manufactured by alkylation
of sodium methanesulfinate with 3-bromopropionitrile to yield methyl-
sulfonylpropionitrile (crude drug substance). The crude drug substance
was then purified by dissolution into acetone, filtration of the sodium bro-
mide byproduct, solvent exchange via distillation, and recrystallization
from ethanol.
Inflammasome Stimulation. Details for NLRP3 inflammasome formation in
HMDM, human neutrophils, and J774A.1 murine macrophages are presented
in SI Appendix.
NLRP3 ATPase Activity. Details for the NLRP3 ATPase activity measurements
can be found in SI Appendix.
Immunoprecipitation. Details for the immunoprecipitation can be found in
SI Appendix.
Immunofluorescent Microscopy and Fluorescent Resonance Energy Transfer
Analysis. J774A.1 cells were stimulated as described above. After washing
with PBS, the cells were fixed and permeated with 70–30 acetone–methanol
as previously described (45). Briefly, cells were placed in a humidified slide
chamber blocked for 1 h in 10% normal donkey serum (Jackson Immuno-
logicals). After removal of the donkey serum, the primary antibodies to
NLRP3 (Cryo-2; AdipoGen), caspase-1 (sc-514; Santa Cruz Biotechnology), and
ASC (D2W8U; Cell Signaling) or isomolar, species-specific anti-IgG (R&D
Systems, Inc.) were added and incubated overnight at 4 °C. The slides were
then washed three times with PBS, and cells were incubated for 1 h at room
temperature with donkey anti-mouse–Alexa555 (Life Technologies) or
donkey anti-rabbit–Alexa488 (Life Technologies) conjugated secondary an-
tibodies. Nuclei were stained with DAPI (Life Technologies). FRET images
were acquired using a Marianas Imaging Station (Intelligent Imaging Inno-
vations) using a Zeiss 639 Plan-Apochromat objective (1.4 N.A.), a Sutter
Xenon light source, and a Cooke SensiCam (The Cooke Corporation) as pre-
viously described (45). The FRET was calculated as FRET = Transfer − (Fd/D) −
(Fa/Aa) as reported (46).
Flow Cytometry. Details on flow cytometry to assess levels of phosphokinases
can be found in SI Appendix.
Whole-Cell Patch-Clamp Recordings. For electrophysiological recordings,
U937 cells were placed in poly-L-lysine–coated cell culture dishes (Nunc) as
previously described (47). Briefly, after incubation with 1 μg/mL LPS from
Escherichia coli (L2654; Sigma-Aldrich) for 5 h, whole-cell patch-clamp re-
cordings were performed at room temperature. Cells were clamped to −60 mV,
Fig. 9. OLT1177 is rapidly absorbed after oral administration. Plasma
OLT1177 concentration versus time after a single oral dose of 100 mg (red),
300 mg (blue), and 1,000 mg (green). n = 5 for each dose group.
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Fig. 8. OLT1177 reduces IL-1β release in peripheral blood mononuclear cells
(PBMCs) from human subjects with NLRP3 mutations. Mean levels of IL-1β in
the supernatants of PBMCs from two patients affected by CAPS. Patient A
(A) represents a severe case of neonatal onset multisystem inflammatory
disease (NOMID) with mutation E567K, and patient B (B) represents a case of
Muckle–Wells syndrome (MWS) with mutation E525K. Cells were stimulated
with LPS (100 ng/mL) for 18 h in the presence of vehicle (PBS) or OLT1177 (1
μM) (OLT). Vehicle and OLT1177 were added 30 min after LPS.
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and transmembrane currents were recorded using an EPC-9 amplifier (HEKA)
and acquired via an ITC-16 interface with Pulse software (HEKA). A 100-mM
stock solution of 2′(3′)-O-(4-benzoylbenzoyl)adenosine-5′-triphosphate tri(trie-
thylammonium) salt (BzATP) (Jena Bioscience) was prepared and dissolved in the
bath solution to a 100-μM working solution and applied via a pressure-driven
microperfusion system.
In Vivo LPS Challenge. Animal protocols were approved by the University of
Colorado Health Sciences Center Animal Care and Use Committee. C57BL/6J
male mice, 22 to 26 g (The Jackson Laboratory), were treated with 200 mg/kg
OLT1177 in 200 μL of saline or the matching volume of vehicle (saline) in-
traperitoneally (i.p.) every 12 h for five doses. One hour after the last dose of
OLT1177 or saline, the animals were injected i.p. with 200 μL of LPS (E. coli,
055:B5; Sigma-Aldrich) at 5 mg/kg and killed after 2 h. Cytokines were
measured in the peritoneal fluid and in homogenates of spleen, lung, liver,
and skeleton muscle (quadriceps). Tissue homogenates were centrifuged at
13,000 × g for 20 min at 4 °C, and the supernatants were assayed for cyto-
kine levels. The cytokine concentrations were corrected for total protein
content. For experiments with peritoneal lavage, 10 mL of cold PBS were
injected in the peritoneal cavity before organ collection. The peritoneal la-
vage fluids were then centrifuged at 1,000 × g for 5 min, and the super-
natants were used for cytokine measurement.
Metabolomics Analysis.Metabolomics analysis was performed, and details can
be found in SI Appendix.
CAPS Patients. Blood samples from two CAPS patients positive for the mu-
tation of the nlrp3 gene were taken after informed consent by patients or
their legal guardian and as approved by the “G. Gaslini” Ethical Board.
Human Safety and Pharmacokinetic Study. Details of the human study can be
found in SI Appendix.
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